SEC Form 3 · accession 0001640334-19-000211
Inmune Bio, Inc. · INMB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy j Schroeder
Director
Period of report
Feb 1, 2019
Accepted (ET)
Feb 8, 2019 · 6:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001711754
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | holding | — | — | — | 166,667 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF3 | $7.80 | holding | — | — | — | — | Apr 1, 2028 | Common Stock | 108,000 | — | D |
Explanation of responses
- F2The shares of the Common Stock are held by CTI Holdings, a company of which Mr. Schroeder is the majority shareholder.
- F3Of these options 30,000 are vested and the remaining options vest at the rate of 3,000 options a month, until options to purchase 108,000 shares of common stock have been granted.